The Department of Justice (DOJ) recently announced its annual National Health Care Fraud Takedown, a sweeping enforcement action spanning 56 federal districts across 45 U.S. states and territories. The operation resulted in charges against 455 defendants, including 90 doctors and other licensed medical professionals in alleged health care fraud and opioid abuse schemes involving more than $6.5 billion in false claims. The takedown reflects early evidence of the DOJ's current white collar enforcement strategy.
The charged cases show where the DOJ is concentrating resources: large-dollar federal health care program fraud, Medicaid fraud, wound care/allograft billing, opioid diversion by licensed professionals, cardiovascular testing allegations tied to patient harm, and cross-border defendants. The DOJ also highlighted fugitive apprehensions outside the U.S. and the use of advanced analytics, including the Data Fusion Center, to move from claims data to investigations more quickly.
The penalty imposition was equally important. The Centers for Medicare and Medicaid Services (CMS) suspended 1,079 providers and revoked billing privileges for an additional 1,403 providers; The U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG) pursued civil monetary settlements, exclusions, and civil monetary penalty actions; DOJ announced civil charges and settlements; the Drug Enforcement Administration (DEA) initiated 928 administrative cases seeking revocation of authority to prescribe or handle controlled substances; and Medicaid charged $518 million in false claims. In other words, the DOJ is pairing prosecutions with payment suspensions, exclusions, recoveries, asset seizures, and licensure-related consequences.
Trends & Key Takeaways
- Shift in DOJ Priorities: The through-line from DOJ's May 2025 White Collar Enforcement Plan to its 2026 Health Care Fraud Takedown is direct. Last year, the DOJ identified waste, fraud, and abuse in health care and other federal programs, along with unlawful narcotics and opioid distribution, as "high-impact areas" for white collar enforcement. The DOJ also emphasized focus, fairness, and efficiency, including attention to serious losses, culpable actors, obstruction, and asset recovery. The 2026 takedown reflects that playbook: it targets alleged fraud against federal health care programs, opioid diversion, international actors, and the proceeds of fraud.
- Use of Data Analytics: The DOJ is combining expanded data-sharing with advanced analytics, artificial intelligence tools, financial intelligence, and interagency collaboration to identify suspect billing patterns. New arrangements give DOJ's Health Care Fraud Unit access to CMS infrastructure for advanced analytics and AI, incorporate Federal Trade Commission (FTC) consumer complaint and Department of Homeland Security (DHS) travel data, and pair those capabilities with CMS claims-processing tools focused on identity verification and program-wide reporting. Through the Data Fusion Center, DOJ has already used these capabilities to identify hard- to-detect billing volumes, surface hospice discharge manipulation, and support the seizure of more than $27 million in alleged "bust-out scheme" proceeds.
- Cross-Border and Multi-Agency Enforcement: The takedown shows that DOJ is increasingly treating health care fraud as a coordinated national and international enforcement problem, not a series of isolated billing cases. For health care providers, that means enforcement risk may arise from multiple directions at once, including the DOJ, HHS-OIG, CMS, DEA, state Medicaid units, and foreign law enforcement partners.
Practical Recommendations
Review and Strengthen Compliance Programs. Providers should evaluate the effectiveness of their existing compliance programs, with particular attention to billing practices, referral arrangements, and documentation integrity. Areas of initial focus should include hospice, home health, wound care, behavioral health, clinical laboratories, and durable medical equipment.
Audit Referral Arrangements and Compensation Structures. The Anti-Kickback Statute continues to be a primary tool of enforcement for the DOJ. Providers should ensure that all referral arrangements, physician compensation models, and marketing activities comply with applicable safe harbors and exceptions.
Assess Medicaid Billing Practices. The record number of Medicaid-related charges signals a significant enforcement pivot. Providers with substantial Medicaid revenue should conduct thorough reviews of their billing and documentation practices.
Prepare for Enhanced Data Surveillance. The government's new data-analytics and AI capabilities mean that anomalous billing patterns are more likely to be detected earlier. Providers should proactively analyze their own claims data for outliers and unusual patterns that could trigger scrutiny.
Evaluate Telehealth and Remote Services Compliance. The new data-sharing agreements, particularly regarding travel data and telemarketing complaints, suggest heightened scrutiny of telehealth and remote monitoring services. Providers offering these services should verify compliance with applicable licensing, billing, and documentation requirements.
Address Potential Issues Proactively. If internal reviews reveal potential compliance issues, providers should consult with experienced counsel regarding the advisability of voluntary self-disclosures under CMS and OIG protocols.
How Baker Donelson Can Help
Baker Donelson's Government Enforcement and Investigations Group regularly advises clients facing white collar enforcement risk. The group assists with compliance assessments, internal investigations, responses to subpoenas and government inquiries, voluntary disclosures, and criminal, civil, and administrative enforcement matters. Clients can turn to this team for practical guidance in assessing risk, engaging with regulators and enforcement agencies, and navigating investigations from early fact development through resolution.